33.30
0.95%
-0.32
Celldex Therapeutics Inc. stock is currently priced at $33.30, with a 24-hour trading volume of 472.71K.
It has seen a -0.95% decreased in the last 24 hours and a -11.01% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $33.86 pivot point. If it approaches the $33.14 support level, significant changes may occur.
Previous Close:
$33.62
Open:
$33.95
24h Volume:
472.71K
Market Cap:
$2.19B
Revenue:
$6.07M
Net Income/Loss:
$-144.88M
P/E Ratio:
-12.61
EPS:
-2.64
Net Cash Flow:
$-120.94M
1W Performance:
-9.80%
1M Performance:
-11.01%
6M Performance:
+10.23%
1Y Performance:
+4.72%
Celldex Therapeutics Inc. Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc.
Sector
Industry
Phone
908-200-7500
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton
Celldex Therapeutics Inc. Stock (CLDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-23 | Initiated | TD Cowen | Outperform |
Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Aug-22-23 | Initiated | Wells Fargo | Underweight |
Sep-17-21 | Initiated | Jefferies | Buy |
Sep-10-21 | Initiated | SVB Leerink | Outperform |
Jul-22-21 | Initiated | Guggenheim | Buy |
Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-07-16 | Initiated | Aegis Capital | Buy |
Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
Mar-01-16 | Initiated | H.C. Wainwright | Buy |
Aug-11-15 | Reiterated | Brean Capital | Buy |
Aug-11-15 | Reiterated | Oppenheimer | Outperform |
Aug-11-15 | Reiterated | ROTH Capital | Buy |
Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
Nov-17-14 | Reiterated | ROTH Capital | Buy |
Mar-04-14 | Reiterated | Oppenheimer | Outperform |
Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Feb-26-13 | Reiterated | Oppenheimer | Outperform |
Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
Oct-02-12 | Reiterated | Oppenheimer | Outperform |
Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc. Stock (CLDX) Latest News
Celldex Therapeutics is Now Oversold (CLDX) - Nasdaq
Nasdaq
In the Green: Celldex Therapeutics Inc. (CLDX) Closes at 35.38, Up/Down -4.17 from Previous Day – DWinneX - The Dwinnex
The Dwinnex
Monashee Investment Management LLC Buys New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
MarketBeat
The growth track for Celldex Therapeutics Inc. (CLDX) has changed recently – Sete News - SETE News
SETE News
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5.4% - MarketBeat
MarketBeat
Charles Schwab Investment Management Inc. Purchases 47,844 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
MarketBeat
Celldex Therapeutics Inc. Stock (CLDX) Financials Data
Celldex Therapeutics Inc. (CLDX) Revenue 2024
CLDX reported a revenue (TTM) of $6.07 million for the quarter ending March 31, 2024, a +92.76% rise year-over-year.
Celldex Therapeutics Inc. (CLDX) Net Income 2024
CLDX net income (TTM) was -$144.88 million for the quarter ending March 31, 2024, a -22.12% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Cash Flow 2024
CLDX recorded a free cash flow (TTM) of -$120.94 million for the quarter ending March 31, 2024, a -10.34% decrease year-over-year.
Celldex Therapeutics Inc. (CLDX) Earnings per Share 2024
CLDX earnings per share (TTM) was -$2.86 for the quarter ending March 31, 2024, a -13.49% decline year-over-year.
Celldex Therapeutics Inc. Stock (CLDX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Feb 13 '24 |
Option Exercise |
3.86 |
24,166 |
93,163 |
25,924 |
Martin Samuel Bates | SVP AND CFO |
Jan 02 '24 |
Option Exercise |
2.78 |
10,750 |
29,885 |
35,128 |
About Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Cap:
|
Volume (24h):